In wortwörtlich beispielhafter Weise veranschaulicht das Werk die tumorähnlichen Läsionen, die Skelettmetastasen und ihre Differenzialdiagnosen. Die Diagnostik von Knochentumoren ist komplex und erfordert umfassende Kenntnisse. Profitieren Sie vom Expertenwissen der Autoren und stellen Sie die richtige Diagnose bzw. grenzen Sie die differenzialdiagnostischen Möglichkeiten ein.

Medizinische Referenzinformation: vollständig, qualitätsgesichert, übersichtlich und aktuell Der stetige Wissenszuwachs und die starke Arbeitsverdichtung in der Medizin machen eine schnelle Verfügbarkeit qualitätsgesicherter Information für eine sichere und effiziente Patientenversorgung unabdingbar. Die Diagnostik von Knochentumoren ist komplex und sowohl für erfahrene als auch weniger erfahrene Ärzte eine immer wiederkehrende Herausforderung. Dieses Werk ist Teil der fächerübergreifenden Referenz-Reihe, die speziell auf die Bedürfnisse klinisch tätiger Ärzte ausgerichtet ist. Im Rahmen von fachlichen Überschneidungen steht dieses Werk im inhaltlichen Austausch mit anderen Referenz-Werken. Profitieren Sie von einem umfassenden und aktuellen Werk mit allen wichtigen Krankheitsbildern und Diagnosekriterien! Ihre Vorteile im Überblick: Medizinisches Fachwissen auf höchstem Niveau: Qualitätsgesicherte Informationen von renommierten Verfassern Maximale Praxisrelevanz: Umfangreiches Bildmaterial und der Bezug zur aktuellen WHO-Klassifikation helfen bei der Einordnung Ihres speziellen Befundes. Ziehen Sie die Referenz während der Bildanalyse zurate! Hohe Übersichtlichkeit: Klare und konsequente Strukturierung der Kapitel für schnelles Nachschlagen und nachhaltiges Einprägen Fokus auf das Wesentliche: Die Inhalte sind für den schnellen Zugriff optimiert, kein mühsames Suchen in langen Textpassagen. Wir bringen die Information für Sie auf den Punkt. Der ideale Begleiter für Ihren Alltag in Klinik und Praxis – diagnostizieren Sie schnell und sicher! Jederzeit zugreifen: Der Inhalt des Buches steht Ihnen ohne weitere Kosten digital in der Wissensplattform eRef zur Verfügung (Zugangscode im Buch). Mit der kostenlosen eRef App haben Sie zahlreiche Inhalte auch offline immer griffbereit.

Nachschlagen, vergleichen, absichern - einfacher geht es nicht! - Differenzialdiagnostischer Wegweiser, einzigartig kombiniert mit radiologischem Atlasteil - Über Entscheidungsbäume und Tabellen gezielt zur Diagnose - Alle relevanten Knochenerkrankungen knapp beschrieben und an typischen Bildbeispielen erklärt - Mit moderner Schnittbilddiagnostik und szintigraphischen Diagnostiktechniken - Einfach, schnell, präzise: Ein Nachschlagewerk, mit dem Sie Schritt für Schritt die richtige Diagnose stellen.

Abstract: The established standard to ensure state-of-the-art cancer treatment is through multidisciplinary tumor boards (TBs), although resource- and time-intensive. In this validation study, the multiple myeloma (MM)-TB was reexamined, aiming to validate our previous (2012-2014) results, now using the TB data from March 2020 to February 2021. We assessed MM-TB protocols, physicians' documentation, patient, disease, remission status, progression-free survival (PFS), and overall survival (OS) as left-truncated survival times. Moreover, TB-adherence, level of evidence according to grade criteria, time requirements, study inclusion rates, and referral satisfaction were determined. Within a 1-year period, 312 discussed patients were documented in 439 TB protocols. Patient and disease characteristics were typical for comprehensive cancer centers. The percentages of patients discussed at initial diagnosis (ID), with disease recurrence or in need of interdisciplinary advice, were 39%, 28%, and 33%, respectively. Reasons for the MM-TB presentation were therapeutic challenges in 80% or staging/ID-defining questions in 20%. The numbers of presentations were mostly one in 73%, two in 20%, and three or more in 7%. The TB adherence rate was 93%. Reasons for non-adherence were related to patients' decisions or challenging inclusion criteria for clinical trials. Additionally, we demonstrate that with the initiation of TBs, that the number of interdisciplinarily discussed patients increased, that TB-questions involve advice on the best treatment, and that levels of compliance and evidence can be as high as ≥ 90%. Advantages of TBs are that they may also improve patients', referrers', and physicians' satisfaction, inclusion into clinical trials, and advance interdisciplinary projects, thereby encouraging cancer specialists to engage in them

Abstract: Currently, there is uncertainty about the predictive factors for metastatic epidural spinal cord compression (MESCC) and consecutive symptomatology in tumor patients. Prognostic algorithms for identifying patients at risk for paralysis are missing. The influence of the pathologic fracture on the patient's symptoms is widely discussed in the literature and we hypothesize that pathologic fractures contribute to spinal cord compression and are therefore predictive of severe paralysis. We tested this hypothesis in 136 patients who underwent surgery for spinal metastases. The most common primary cancers were prostate (24.3%, n = 33), breast (11.0%, n = 15), lung (10.3%, n = 14), and cancer of unknown primary (10.3%, n = 14). MESCC primarily affected the thoracic (77.2%, n = 105), followed by the lumbar (13.2%, n = 18) and cervical (9.6%, n = 13) spine. Pathologic fractures occurred in 63.2% (n = 86) of patients, mainly in osteolytic metastases. On the American spinal injury association (ASIA) impairment scale (AIS), 63.2% (n = 86) of patients exhibited AIS grade D and 36.8% (n = 50) AIS grade C-A preoperatively. The presence of a pathologic fracture alone did not predict severe paralysis (AIS C-A, p = 0.583). However, the duration of sensorimotor impairments, patient age, spinal instability neoplastic score (SINS), and the epidural spinal cord compression (ESCC) grade together predicted severe paralysis (p = 0.006) as did the ESCC grade 3 alone (p = 0.028). This is in contrast to previous studies that stated no correlation between the degree of spinal cord compression and the severity of neurologic impairments. Furthermore, the high percentage of pathologic fractures found in this study is above previously reported incidences. The risk factors identified can help to predict the development of paralysis and assist in the improvement of follow-up algorithms and the timing of therapeutic interventions

Abstract: Background Skeletal-related events (SREs) due to bone metastases (BM) significantly impact the morbidity and mortality of cancer patients. The present study sought to investigate clinicopathological characteristics, metastasis-free survival (MFS), and SREs in patients referred to a tertiary orthopedic and trauma center. Methods Data were retrieved from electronic health records (n=628). Survival curves were estimated utilizing the Kaplan-Meier method. The Cox regression model was used to determine factors influencing MFS based on estimated hazard ratios (HRs). Results Breast (55.8%) and lung (18.2%), and lung (32.9%) and prostate (16.8%) cancer were the most common cancer types in our cohort in women and men, respectively. Fifteen percent of patients presented with BM as the first manifestation of tumor disease, 23% had metastasis diagnosis on the same day of primary tumor diagnosis or within 3 months, and 62% developed BM at least 3 months after primary tumor diagnosis. Osteolytic BM were predominant (72.3%) and most commonly affecting the spine (23%). Overall median MFS was 45 months (32 (men) vs. 53 (women) months). MFS was shortest in the lung (median 15 months, 95% CI 8.05-19) and longest in breast cancer (median 82 months, 95% CI 65.29-94). Age (≥ 60 vs. 60 years) and primary cancer grading of ≥2 vs. 1 revealed prognostic relevance.brbrConclusion